1ST Source Bank cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,942 shares of the financial services provider’s stock after selling 835 shares during the period. 1ST Source Bank’s holdings in iShares Biotechnology ETF were worth $1,975,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF during the third quarter valued at $29,000. HHM Wealth Advisors LLC grew its holdings in iShares Biotechnology ETF by 200.0% during the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Bradley & Co. Private Wealth Management LLC bought a new position in iShares Biotechnology ETF during the fourth quarter valued at $32,000. Newbridge Financial Services Group Inc. bought a new position in shares of iShares Biotechnology ETF in the fourth quarter worth $33,000. Finally, Hager Investment Management Services LLC bought a new position in shares of iShares Biotechnology ETF in the fourth quarter worth $34,000. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Price Performance
iShares Biotechnology ETF stock opened at $134.19 on Monday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The business has a fifty day moving average price of $136.25 and a 200-day moving average price of $139.76. The firm has a market capitalization of $6.34 billion, a P/E ratio of 24.52 and a beta of 0.84.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- How to invest in marijuana stocks in 7 stepsĀ
- How to Build the Ultimate Everything ETF Portfolio
- How Can Investors Benefit From After-Hours Trading
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Choose Top Rated Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.